Inhibitory Effects of a Novel PPAR-γ Agonist MEKT1 on Pomc Expression/ACTH Secretion in AtT20 Cells
Although therapeutic effects of the peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists rosiglitazone and pioglitazone against Cushing’s disease have been reported, their effects are still controversial and inconsistent. We therefore examined the effects of a novel PPAR-γ agonist, MEK...
Saved in:
Main Authors: | Rehana Parvin, Erika Noro, Akiko Saito-Hakoda, Hiroki Shimada, Susumu Suzuki, Kyoko Shimizu, Hiroyuki Miyachi, Atsushi Yokoyama, Akira Sugawara |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2018-01-01
|
Series: | PPAR Research |
Online Access: | http://dx.doi.org/10.1155/2018/5346272 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
PPAR Agonists and Cardiovascular Disease in Diabetes
by: Anna C. Calkin, et al.
Published: (2008-01-01) -
PPAR Agonists for the Prevention and Treatment of Lung Cancer
by: Sowmya P. Lakshmi, et al.
Published: (2017-01-01) -
Cannabinoids: A New Group of Agonists of PPARs
by: Yan Sun, et al.
Published: (2007-01-01) -
AMPK-Dependent Metabolic Regulation by PPAR Agonists
by: Woo Hyung Lee, et al.
Published: (2010-01-01) -
PPARα-Independent Arterial Smooth Muscle Relaxant Effects of PPARα Agonists
by: Neerupma Silswal, et al.
Published: (2012-01-01)